Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-04-05
2005-04-05
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
06875753
ABSTRACT:
The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF.
REFERENCES:
patent: 4141973 (1979-02-01), Balazs
patent: 4725585 (1988-02-01), Wenge et al.
patent: 5079236 (1992-01-01), Drizen et al.
patent: 5646129 (1997-07-01), Callegaro et al.
patent: 5817644 (1998-10-01), Gustafson
patent: 5827834 (1998-10-01), Falk et al.
patent: 5914314 (1999-06-01), Falk et al.
patent: 6013641 (2000-01-01), Lussow et al.
patent: 6069135 (2000-05-01), Falk et al.
patent: 1205031 (1986-05-01), None
patent: WO 9104058 (1991-04-01), None
patent: WO9104058 (1991-04-01), None
patent: WO 9316732 (1993-09-01), None
patent: WO 9316733 (1993-09-01), None
patent: WO 9423725 (1994-10-01), None
patent: WO 9530423 (1995-11-01), None
patent: WO9605845 (1996-02-01), None
patent: WO 9606622 (1996-03-01), None
patent: WO 9703699 (1997-02-01), None
patent: WO 9715330 (1997-05-01), None
patent: WO 9725051 (1997-07-01), None
patent: WO 9813024 (1998-04-01), None
patent: WO 9817320 (1998-04-01), None
patent: WO 9852590 (1998-11-01), None
patent: WO 9955230 (1999-11-01), None
Hamann et al,Journal of Immunology1995, 154(8), 4073-80.*
Han et al.Journal of Cellular Physiology1996, 168(1), 97-104.*
Alho et al.,J. Cell. Biol., 108, 1557-1565 (1989).
Kelley et al.,J. Dermatol. Surg. Oncol., 16(11), 1039-1042 (1990).
Martindale The ExtraPharmacopoeia, Reynolds et al. Editors, The Pharmaceutical Press, London, pp. 234-235 (1982).
The Merch Index, Ninth Edition, Merch & Co., Inc., Rahway, New Jersey, p. 407, No. 3058 (1976).
Trabucchi et al.,Int. J. Tiss. Reac., VIII(6), 533-544 (1986).
Webster's Ninth New College Dictionary, Merriam-Webster Inc., Springfiled, Massachusetts, p. 1256 (1990).
West et al.,Experimental Cell Research, 183, 179-196 (1989).
Gowland G., et al Marked Enhanced Efficacy of Cyclosporin When Combined With Hyaluronic Acid Evidence From Two T Cell-Mediated Models.Clinical Drug Investigation, vol. 11, No. 4, 1996, pp. 245-250, XPOOO613356.
Toole, B.P. Hyaluronan and its binding proteins, the hyaladherins.Curr. Opin. Cell. Biol. 2: 839-844 (1990).
Toole, B.P. Development role of hyaluronate.Conn. Tiss. Res. 10: 93-100 (1982).
Entwistle, J. Zhang, S., Yang, B., Wong, C. Hall, C.L., Curpen, G., Mowat M., Greenberg, A.H., and Tutley, E.A. Cloning and characterization of the gene encoding the hyaluronan receptor RHAMM; the role of a secreted isoform in the regulation of focal adhesion formation.Gene 163: 233-238 (1995).
Yang, B., Yang, X. Zhang, S., Turley, M., Samuel, S., Savani, R.C., Greenberg, A.H., and Turley, E.A. Overexpression of the hyaluronan receptor RHAMM is transforming, and is required for H-ras transformation.Cell 82: 19-28 (1995).
Masellis-Smith, A., Belch, A.R., Mant, M.J., Turley, E.A., and Pilarski., L.M. Hyaluronan-dependent motility of B cells and leukemic plasma cells in multiple myeloma: Alternate usage of RHAMM and CD44.Blood 81: 1891-1899 (1996).
Turley, E.A., Belch, A.R., Poppema, S., and Pilarski, L.M. Expression and function of a receptor for hyaluronan-mediated motility (RHAMM) on normal and malignant B lymphocytes.Blood 81: 446-453 (1993).
Pilarski, L.M., Miszta, H., and Turley, E.A. Regulation expression of a receptor for hyaluronan-mediated motility RHAMM on human thymocytes and T cells.J. Immunol. 150: 4292-4302 (1993).
S. K.B., McCoshen, J., Kredentser, J., and Turley, E. The Regulation of Sperm Motlity by a Novel Hyaluronan Receptor.Fertility and Sterility 61: 935-940 (1994).
Turely, E.A., Sossain, M.Z., Sorokan, T., Jordan, L.M. and Nagy, J.I. Astrocyte and microglial motility in vitro is funtionally dependent on the hyaluronan receptor RHAMM.Glia 12: 68-80 (1994).
Golub, E.S., Green, D.R. Immunology A Synthesis. 2:205, (1991).
Kuby, J. Immunology 3:50; (1997).
Roitt, I., Brostoff, J., Male, D. Immunology 4:2.1 , date 1996.
Weaver, C.H., Hazeltonn, B., Birch, R., Palmer, P., Allen, A., Schwwartzberg, L. and West, W. An analysis of engraftment Kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy.Blood 86: 3961-3969 (1995).
Boiron, J.M., Marit, G., Faberes, C., Cony-Makhoul, P., Foures, C., Ferrer, A.M., Cristol, G., Sarrat, A., Girault, D., and Reiffers, J. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF).Bone Marrow Transplantation 12: 49-55 (1993).
Schiller, G., Vescio, R., Freytes, C., Spitzer, G., Sahebi, F., Lee, M., Wu, S.H., Cao, J., Lee, J.C., Hong, C.H. Lichtenstein, A., Lill, M., Hall, J., Berenson, R., and Berenson, J. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.Blood 86: 390-397 (1995).
Maier Leigh C.
Pillsbury & Winthrop LLP
The Governors of the University of Alberta
Wilson James O.
LandOfFree
Methods for cell mobilization using in vivo treatment with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for cell mobilization using in vivo treatment with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for cell mobilization using in vivo treatment with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3371677